Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Tiziana Life Sciences filed for FDA Orphan Drug Designation for intranasal foralumab to treat Multiple System Atrophy. A Phase 2a open-label MSA study is underway assessing microglial activation, clinical outcomes, and safety.Material DetailsContext by AI AnalystThis is an early regulatory step aug…
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, toda…
Tiziana Life Sciences files with the FDA for orphan drug designation for intranasal foralumab for the treatment of multiple system atrophy (MSA).